請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65174
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳嘉文(Chia-Wen Wu) | |
dc.contributor.author | Yu-Te Liao | en |
dc.contributor.author | 廖祐德 | zh_TW |
dc.date.accessioned | 2021-06-16T23:28:26Z | - |
dc.date.available | 2014-08-01 | |
dc.date.copyright | 2012-08-01 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-31 | |
dc.identifier.citation | 1 Slowing, I. I., Vivero-Escoto, J. L., Wu, C.-W. & Lin, V. S. Y. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Delivery Rev. 60, 1278-1288, (2008).
2 Zhang, C. M. et al. Self-activated luminescent and mesoporous strontium hydroxyapatite nanorods for drug delivery. Biomaterials 31, 3374-3383, (2010). 3 Doshi, N. & Mitragotri, S. Designer Biomaterials for Nanomedicine. Adv. Funct. Mater. 19, 3843-3854, (2009). 4 Bangham, A. D. & Horne, R. W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in electron microscope. J. Mol. Biol. 8, 660-&, (1964). 5 Matsumoto, T. et al. Modification of apatite materials for bone tissue engineering and drug delivery carriers. Curr. Med. Chem. 14, 2726-2733, (2007). 6 Panyam, J. & Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Delivery Rev. 55, 329-347, (2003). 7 Brigger, I., Dubernet, C. & Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Delivery Rev. 54, 631-651, (2002). 8 Singh, R. & Lillard, J. W., Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86, 215-223, (2009). 9 Letchford, K. & Burt, H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 65, 259-269, (2007). 10 Torchilin, V. P. Multifunctional nanocarriers. Adv. Drug Delivery Rev. 58, 1532-1555, (2006). 11 Jatzkewitz, H. An ein kolloidales blutplasmaersatzmittel (polyvinylpyrrolidon) gebundenes peptamin (glycyl-l-leucyl-mezcalin) als neuartige depotform fur biologisch aktive primare amine (mezcalin). Z. Naturforsch. 10, 27-31, (1955). 12 Chiou, W. L. & Smith, L. D. Solid dispersion approach to the formulation of organic liquid drugs using polyethylene glycol 6000 as a carrier. J. Pharm. Sci. 60, 125-127, (1971). 13 Molteni, L. Dextran and inulin conjugates as drug carriers. Methods Enzymol. 112, 285-298, (1985). 14 Shen, W. C. & Ryser, H. J. P. Poly(l-lysine) has different membrane-transport and drug-carrier properties when complexed with heparin. 78, 7589-7593, (1981). 15 Kawaguchi, H. Functional polymer microspheres. Prog. Polym. Sci. 25, 1171-1210, (2000). 16 Jones, M. C. & Leroux, J. C. Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 48, 101-111, (1999). 17 Peppas, N. A., Keys, K. B., Torres-Lugo, M. & Lowman, A. M. Poly(ethylene glycol)-containing hydrogels in drug delivery. J. Controlled Release 62, 81-87, (1999). 18 Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discovery 9, 615-627, (2010). 19 Thakur, G. et al. Crosslinking of gelatin-based drug carriers by genipin induces changes in drug kinetic profiles in vitro. J. Mater. Sci. - Mater. Med. 22, 115-123, (2011). 20 Joshi, A., Keerthiprasad, R., Jayant, R. D. & Srivastava, R. Nano-in-micro alginate based hybrid particles. Carbohydr. Polym. 81, 790-798, (2010). 21 Miyazaki, S., Ishii, K. & Nadai, T. The use of chitin and chitosan as drug carriers. Chem. Pharm. Bull. 29, 3067-3069, (1981). 22 Kristl, J., Smidkorbar, J., Struc, E., Schara, M. & Rupprecht, H. Hydrocolloids and gels of chitosan as drug carriers. Int. J. Pharm. 99, 13-19, (1993). 23 Won, C. Y., Chu, C. C. & Yu, T. J. Synthesis of starch-based drug carrier for the control/release of estrone hormone. Carbohydr. Polym. 32, 239-244, (1997). 24 Wolf, B., Horsch, W. & Finke, I. The use of bead celluloses as carrier for controlled liberation of drugs .2. methods of characterization of bead cellulose and results of examination upon a home-made preparation. 46, 788-792, (1991). 25 Cameroni, R., Forni, F., Iannuccelli, V., Coppi, G. & Bernabei, M. T. Montmorillonite as a drug carrier study of the release of papaverine from the complex with veegum. Farmaco Edizione Pratica 40, 283-295, (1985). 26 Xu, Z. P., Zeng, Q. H., Lu, G. Q. & Yu, A. B. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem. Eng. Sci. 61, 1027-1040, (2006). 27 Kim, S., Shibata, E., Sergiienko, R. & Nakamura, T. Purification and separation of carbon nanocapsules as a magnetic carrier for drug delivery systems. Carbon 46, 1523-1529, (2008). 28 Tomoda, K., Ariizumi, H., Nakaji, T. & Makino, K. Hydroxyapatite particles as drug carriers for proteins. Colloids Surf., B 76, 226-235, (2010). 29 Mizushima, Y. et al. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. J. Controlled Release 110, 260-265, (2006). 30 Wu, K. C. W. et al. Biocompatible, surface functionalized mesoporous titania nanoparticles for intracellular imaging and anticancer drug delivery. Chem. Commun. 47, 5232-5234, (2011). 31 Yang, Q. et al. pH-responsive carrier system based on carboxylic acid modified mesoporous silica and polyelectrolyte for drug delivery. Chem. Mater. 17, 5999-6003, (2005). 32 Gu, J., Su, S., Li, Y., He, Q. & Shi, J. Hydrophilic mesoporous carbon nanoparticles as carriers for sustained release of hydrophobic anti-cancer drugs. Chem. Commun. 47, 2101-2103, (2011). 33 Ajima, K. et al. Carbon nanohorns as anticancer drug carriers. Mol. Pharmaceutics 2, 475-480, (2005). 34 Vallet-Regi, M. & Ruiz-Hernandez, E. Bioceramics: from bone regeneration to cancer nanomedicine. Adv. Mater. 23, 5177-5218, (2011). 35 Chen, J. Z., Shi, Y. l., Wang, L., Yan, F. y. & Zhang, F. q. Preparation and properties of hydroxyapatite-containing titania coating by micro-arc oxidation. Mater. Lett. 60, 2538-2543, (2006). 36 Sonvico, F. et al. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: Synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chem. 16, 1181-1188, (2005). 37 Kawano, T. et al. Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. J. Controlled Release 111, 382-389, (2006). 38 Park, C., Oh, K., Lee, S. C. & Kim, C. Controlled release of guest molecules from mesoporous silica particles based on a pH-responsive polypseudorotaxane motif. Angew. Chem., Int. Ed. 46, 1455-1457, (2007). 39 Tripathi, B. P. & Shahi, V. K. Organic-inorganic nanocomposite polymer electrolyte membranes for fuel cell applications. Prog. Polym. Sci. 36, 945-979, (2011). 40 Ren, H. y., Zhu, M. f. & Haraguchi, K. Characteristic swelling-deswelling of polymer/clay nanocomposite gels. Macromolecules 44, 8516-8526, (2011). 41 Low, P. S., Henne, W. A. & Doorneweerd, D. D. Discovery and development of folic-acid-based receptor targeting for Imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 41, 120-129, (2008). 42 Huang, X. M. et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275, 547-550, (1997). 43 Farokhzad, O. C. et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 103, 6315-6320, (2006). 44 Ferdinandi, E. S. et al. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2. Cancer Chemother. Pharmacol. 68, 193-205, (2011). 45 Soudy, R., Gill, A., Sprules, T., Lavasanifar, A. & Kaur, K. Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells. J. Med. Chem. 54, 7523-7534, (2011). 46 Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22, (2010). 47 Aoki, Y., Hosaka, S., Kawa, S. & Kiyosawa, K. Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif. Cancer Gene Ther. 8, 783-787, (2001). 48 Desgrosellier, J. S. et al. An integrin avb3-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat. Med. 15, 1163-U1189, (2009). 49 Auernheimer, J., Haubner, R., Schottelius, M., Wester, H. J. & Kessler, H. Radio-analytical determination of the coating efficiency of cyclic RGD peptides. Helvetica Chim. Acta 89, 833-840, (2006). 50 Jain, S. et al. RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int. J. Pharm. 261, 43-55, (2003). 51 Cheng, Z., Wu, Y., Xiong, Z. M., Gambhir, S. S. & Chen, X. Y. Near-infrared fluorescent RGD peptides for optical imaging of integrin avb3 expression in living mice. Bioconjugate Chem. 16, 1433-1441, (2005). 52 Yanagisawa, T., Shimizu, T., Kuroda, K. & Kato, C. The preparation of alkyltrimethylammonium-kanemite complexes and their conversion to microporous materials. Bull. Chem. Soc. Jpn. 63, 988-992, (1990). 53 Beck, J. S. et al. A new family of mesoporous molecular-sieves prepared with liquid-crystal templates. J. Am. Chem. Soc. 114, 10834-10843, (1992). 54 Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C. & Beck, J. S. Ordered mesoporous molecular-sieves synthesized by a liquid-crystal template mechanism. Nature 359, 710-712, (1992). 55 Ikeue, K., Miyoshi, N., Tanaka, T. & Machida, M. Ca-containing mesoporous silica as a solid base catalyst for the knoevenagel condensation reaction. Catal. Lett. 141, 877-881, (2011). 56 Sakamoto, Y., Nagata, K., Yogo, K. & Yamada, K. Preparation and CO2 separation properties of amine-modified mesoporous silica membranes. Microporous Mesoporous Mater. 101, 303-311, (2007). 57 Tan, J., Wang, H. F. & Yan, X. P. Discrimination of saccharides with a fluorescent molecular imprinting sensor array based on phenylboronic acid functionalized mesoporous silica. Anal. Chem. 81, 5273-5280, (2009). 58 Nakahira, A., Nagata, H., Onoki, T. & Yamasaki, Y. Evaluation of microstructures and properties of bulk mesoporous silica. Res. Chem. Intermed. 34, 347-352, (2008). 59 Hu, Y. et al. 3D cubic mesoporous silica microsphere as a carrier for poorly soluble drug carvedilol. Microporous Mesoporous Mater. 147, 94-101, (2012). 60 Grosso, D. et al. Two-dimensional hexagonal mesoporous silica thin films prepared from black copolymers: Detailed characterization amd formation mechanism. Chem. Mater. 13, 1848-1856, (2001). 61 Vartuli, J. C. et al. Synthesis of mesoporous materials - liquid-crystal templating versus intercalation of layered silicates. Chem. Mater. 6, 2070-2077, (1994). 62 Ying, J. Y., Mehnert, C. P. & Wong, M. S. Synthesis and applications of supramolecular-templated mesoporous materials. Angew. Chem.-Int. Edit. 38, 56-77, (1999). 63 Firouzi, A. et al. Cooperative organization of inorganic-surfactant and biomimetic assemblies. Science 267, 1138-1143, (1995). 64 Skjakbraek, G., Grasdalen, H. & Larsen, B. Monomer sequence and acetylation pattern in some bacterial alginates. Carbohydr. Res. 154, 239-250, (1986). 65 Clark, A. H. & Rossmurphy, S. B. Structural and mechanical-properties of bio-polymer gels. Adv. Polym. Sci. 83, 57-192, (1987). 66 Rees, D. A. Polysaccharide shapes and their interactions - some recent advances. Pure Appl. Chem. 53, 1-14, (1981). 67 Rees, D. A. & Welsh, E. J. Secondary and tertiary structure of polysaccharides in solutions and gels. Angew. Chem., Int. Ed. 16, 214-223, (1977). 68 Gacesa, P. Alginates. Carbohydr. Polym. 8, 161-182, (1988). 69 Novikova, L. N. et al. Alginate hydrogel and matrigel as potential cell carriers for neurotransplantation. J. Biomed. Mater. Res., Part A 77A, 242-252, (2006). 70 Tan, W. H. & Takeuchi, S. Monodisperse alginate hydrogel microbeads for cell encapsulation. Adv. Mater. 19, 2696-2701, (2007). 71 Knill, C. J. et al. Alginate fibres modified with unhydrolysed and hydrolysed chitosans for wound dressings. Carbohydr. Polym. 55, 65-76, (2004). 72 West, T. P. & Preece, J. E. Bulk alginate encapsulation of Hibiscus moscheutos nodal segments. PLANT CELL TISS ORG 97, 345-351, (2009). 73 Srivastava, R. & McShane, M. J. Application of self-assembled ultra-thin film coatings to stabilize macromolecule encapsulation in alginate microspheres. J. Microencapsulation 22, 397-411, (2005). 74 Andresen, I. L., Skipnes, O. & Smidsrod, O. Some biological functions of matrix components in bentic algae in relation to chemistry of their polysaccharides and composition of sea-water. Abstr. Papers Am. Chem. Soc., 50-50, (1976). 75 Gombotz, W. R. & Wee, S. F. Protein release from alginate matrices. Adv. Drug Delivery Rev. 31, 267-285, (1998). 76 Mumper, R. J., Hoffman, A. S., Puolakkainen, P. A., Bouchard, L. S. & Gombotz, W. R. Calcium-alginate beads for the oral delivery of transforming growth factor-beta(1) (tgf-beta(1)) - stabilization of tgf-beta(1) by the addition of polyacrylic-acid within acid-treated beads. J. Controlled Release 30, 241-251, (1994). 77 Coradin, T. & Livage, J. Mesoporous alginate/silica biocomposites for enzyme immobilisation. C. R. Chim. 6, 147-152, (2003). 78 Spargo, B. J., Rudolph, A. S. & Rollwagen, F. M. Recruitment of tissue resident cells to hydrogel composites - in-vivo response to implant materials. Biomaterials 15, 853-858, (1994). 79 Chickering, D. E. & Mathiowitz, E. Bioadhesive microspheres .1. a novel electrobalance-based method to study adhesive interactions between individual microspheres and intestinal-mucosa. J. Controlled Release 34, 251-262, (1995). 80 Motwani, S. K. et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur. J. Pharm. Biopharm. 68, 513-525, (2008). 81 Joseph, I. & Venkataram, S. Indomethacin sustained release from alginate-gelatin or pectin-gelatin coacervates. Int. J. Pharm. 126, 161-168, (1995). 82 Martinez, A. et al. Synthesis and characterization of thiolated alginate-albumin nanoparticles stabilized by disulfide bonds. Evaluation as drug delivery systems. Carbohydr. Polym. 83, 1311-1321, (2011). 83 Sanli, O., Karaca, I. & Isiklan, N. Preparation, characterization, and salicylic acid release behavior of chitosan/poly(vinyl alcohol) blend microspheres. J. Appl. Polym. Sci. 111, 2731-2740, (2009). 84 Zhang, Y. L., Wei, W., Lv, P. P., Wang, L. Y. & Ma, G. H. Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin. Eur. J. Pharm. Biopharm. 77, 11-19, (2011). 85 Moghadam, H., Samimi, M., Samimi, A. & Khorram, M. Electrospray modeling of highly viscous and non-newtonian liquids. J. Appl. Polym. Sci. 118, 1288-1296, (2010). 86 Chan, E. S., Lim, T. K., Ravindra, P., Mansa, R. F. & Islam, A. The effect of low air-to-liquid mass flow rate ratios on the size, size distribution and shape of calcium alginate particles produced using the atomization method. J. Food Eng. 108, 297-303, (2012). 87 Haufova, P., Knejzlik, Z., Jaroslav, H., Zadrazil, A. & Stepanek, F. Reversible buckling and diffusion properties of silica-coated hydrogel particles. J. Colloid Interface Sci. 357, 109-115, (2011). 88 Lim, S. Y., Kim, K. O., Kim, D. M. & Park, C. B. Silica-coated alginate beads for in vitro protein synthesis via transcription/translation machinery encapsulation. J. Biotechnol. 143, 183-189, (2009). 89 Yadav, G. D. & Jadhav, S. R. Synthesis of reusable lipases by immobilization on hexagonal mesoporous silica and encapsulation in calcium alginate: Transesterification in non-aqueous medium. Microporous Mesoporous Mater. 86, 215-222, (2005). 90 Yang, Y. J. et al. Mesoporous silica nanotubes coated with multilayered polyelectrolytes for pH-controlled drug release. Acta Biomaterialia 6, 3092-3100, (2010). 91 Espinosa, E., Zamora, P., Feliu, J. & Baron, M. G. Classification of anticancer drugs - a new system based on therapeutic targets. Cancer Treat Rev 29, 515-523, (2003). 92 Wu, X. Z. A new classification system of anticancer drugs - Based on cell biological mechanisms. Med Hypotheses 66, 883-887, (2006). 93 Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem. Pharmacol. 57, 727-741, (1999). 94 Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J. & Joenje, H. Doxorubicin (adriamycin) - a critical-review of free radical-dependent mechanisms of cytotoxicity. Pharmacol. Ther. 47, 219-231, (1990). 95 Froelichammon, S. J. & Osheroff, N. Topoisomerase poisons - harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270, 21429-21432, (1995). 96 Binaschi, M., Capranico, G., DalBo, L. & Zunino, F. Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol. Pharmacol. 51, 1053-1059, (1997). 97 Capranico, G., Riva, A., Tinelli, S., Dasdia, T. & Zunino, F. Markedly reduced levels of anthracycline-induced dna strand breaks in resistant p388 leukemia-cells and isolated-nuclei. Cancer Res. 47, 3752-3756, (1987). 98 Zunino, F., Pratesi, G. & Perego, P. Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem. Pharmacol. 61, 933-938, (2001). 99 Herrero, E. P., Del Valle, E. M. M. & Galan, M. A. Development of a new technology for the production of microcapsules based in atomization processes. Chem. Eng. J. 117, 137-142, (2006). 100 Rizk, N. K. & Lefebvre, A. H. The influence of liquid-film thickness on airblast atomization. Journal of Engineering for Power-Transactions of the Asme 102, 706-710, (1980). 101 Xu, S. W., Jiang, Z. Y., Lu, Y., Wu, H. & Yuan, W. K. Preparation and catalytic properties of novel alginate-silica-dehydrogenase hybrid biocomposite beads. Ind. Eng. Chem. Res. 45, 511-517, (2006). 102 Shimoda, A., Sawada, S. & Akiyoshi, K. Cell Specific Peptide-Conjugated Polysaccharide Nanogels for Protein Delivery. Macromol. Biosci. 11, 882-888, (2011). 103 Rowley, J. A., Madlambayan, G. & Mooney, D. J. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 20, 45-53, (1999). 104 Yu, K. O. et al. Toxicity of amorphous silica nanoparticles in mouse keratinocytes. J. Nanopart. Res. 11, 15-24, (2009). 105 Choi, K. Y. et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 5, 8591-8599, (2011). 106 Brandhonneur, N. et al. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur. J. Pharm. Sci. 36, 474-485, (2009). 107 Gratton, S. E. A. et al. The effect of particle design on cellular internalization pathways. 105, 11613-11618, (2008). 108 Rosenholm, J. M. et al. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano 3, 197-206, (2009). 109 Tedja, R., Lim, M., Amal, R. & Marquis, C. Effects of serum adsorption on cellular uptake profile and consequent impact of titanium dioxide nanoparticles on human lung cell lines. ACS Nano 6, 4083-4093, (2012). 110 Xu, Q. et al. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 33, 1627-1639, (2012). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65174 | - |
dc.description.abstract | 本論文著重於合成包覆中孔洞氧化矽之海藻酸微米顆粒(MSN@Alg),並且將MSN@Alg應用於穩定釋放以及標靶化療。我們以空氣動力噴霧法為基礎合成MSN@Alg,在此系統下我們藉由調控海藻酸合成濃度、海藻酸流量、氣體流量、噴嘴與氯化鈣槽之距離以及氯化鈣槽之轉速來等不同之參數以合成不同的海藻酸微米顆粒粒徑與型態。舉例來說,當海藻酸合成濃度為1%,海藻酸流量為0.5 mL/min,氣體流量為500 mbar,噴嘴與氯化鈣槽之距離為6 cm,氯化鈣槽之轉速為300 r.p.m時,在海藻酸溶液中加入0.3%之中孔洞氧化矽(MSN),可成功合成出分布集中直徑約為20 um之球型之包覆中孔洞氧化矽海藻酸微米顆粒。接著在海藻酸表面修飾RGD胜肽鏈用於針對特定細胞,並提升藥物治療效果。
以羅丹明6G(rhodamine 6G,R6G)為模擬藥物比較MSN以及MSN@Alg兩者在不同海藻酸濃度以及不同磷酸緩衝液濃度時的吸附以及釋放特性曲線。隨著海藻酸以及磷酸量的改變MSN@Alg具有不同的釋放曲線,當磷酸緩衝液(10 mM)與MSN@Alg之比例為2 毫升比1毫克時具有較佳的穩定釋放效果,而其釋放時間可延長至20天(在此條件下MSN只能維持約10小時的延長釋放)。 將阿黴素(Dox)搭載於MSN內部後,比較有無標靶性質的材料對於具有無標靶受體之細胞的治療效果。由細胞存活率可知,即使載體濃度提高到10 mg/mL對於正常細胞以及癌細胞皆不具有明顯生物毒性(存活率大於80%)。當載體具有標靶配體時,其對於具有標靶受體的癌細胞(HepG2)之治療效果提升約3.5倍;而對於不具有標靶受體之癌細胞(BT20)之治療效果則無明顯差異。 | zh_TW |
dc.description.abstract | This study reports the synthesis of mesoporous silica nanoparticles encapsulated alginate microparticles (MSN@Alg) for sustained release and targeting chemotherapy. The MSN@Alg was synthesized by air dynamical atomization, and the effects of several critical factors including concentration of alginate solution, flow rate of alginate solution, flow rate of air, the distance between nozzle and calcium bath, and stirring rate of calcium on the particle size of the synthesized MSN@Alg were investigated. For example, an uniformly distributed, spherical MSN@Alg with 20 um in diameter could be successfully produced when the reaction conditions were chosen as follows: the concentration of alginate solution was 1%, the flow rate of alginate solution was 0.5 mL/min, the flow rate of air was 500 mbar/cm2, the length between nozzle and calcium bath was 6 cm, and the rate of stirring of calcium bath was 300 r.p.m. with 0.3% MSN.
For studying the sustained release properties of the MSN@Alg, rhodamine 6G (R6G) was used as a model drug, and we compared the release properties of R6G/MSN and R6G/MSN@Alg by using different concentrations of alginate, concentrations and volumes of PBS buffer solutions. The sustained release behavior of the R6G/MSN@Alg system can be prolonged to 20 days with an optimal condition of 1 mg R6G/MSN@Alg to 2 mL PBS (10 mM). For specific targeting chemotherapy, an anti-cancer drug, doxorubicin (Dox), was used to loaded into MSN@Alg, and a RGD-based peptide was functionalized onto the surface of MSN@Alg for the purpose of specific targeting. The results showed that the intracellular drug delivery efficiency was greatly enhanced (i.e, 3.5 folds) for the Dox/MSN@Alg/RGD drug delivery system. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T23:28:26Z (GMT). No. of bitstreams: 1 ntu-101-R99524076-1.pdf: 5627590 bytes, checksum: 8263f769417f3638cc7fe3f7242440e2 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 第1章 緒論 1
第2章 文獻回顧 4 2-1 藥物載體 4 2-1-1 藥物載體的發展與沿革 4 2-1-2 有機材料應用於藥物載體 5 2-1-3 無機材料應用於藥物載體 6 2-1-4 有機-無機複合材料應用於藥物載體 7 2-2 標靶療法 8 2-2-1 標靶療法簡介 8 2-2-2 非選擇性標靶 8 2-2-3 選擇性標靶 9 2-3 中孔洞氧化矽奈米顆粒 10 2-3-1 中孔洞氧化矽奈米顆粒簡介 10 2-3-2 中孔洞氧化矽奈米顆粒製備方式 13 2-4 海藻酸 15 2-4-1 海藻酸簡介 15 2-4-2 海藻酸鈣顆粒製備方式 18 2-5 海藻酸-氧化矽形成複合材料 20 2-5-1 氧化矽包覆海藻酸之複合材料 20 2-5-2 海藻酸包覆氧化矽之複合材料 21 2-6 穩定釋放 22 2-7 抗癌藥物 23 2-7-1 抗癌藥物分類 23 2-7-2 阿黴素介紹與藥理機制 24 第3章 實驗方法 30 3-1 藥品 30 3-2 合成方法 31 3-2-1 實驗總流程 31 3-2-2 中孔洞氧化矽奈米顆粒之製備方法 32 3-2-3 利用中孔洞氧化矽奈米顆粒搭載模擬藥物羅丹明6G與藥物阿黴素之方法 33 3-2-4 海藻酸鈣球與海藻酸鈣包覆中孔洞氧化矽奈米顆粒形成複合材料之製備方法 33 3-2-5 於海藻酸鈣表面修飾短胜肽鏈RGD之方法 35 3-2-6 細胞培養 36 3-3 儀器檢定 36 3-3-1 比表面積分析儀 36 3-3-2 掃描式電子顯微鏡 36 3-3-3 光學顯微鏡 36 3-3-4 粒徑分析儀 36 3-3-5 介面電位分析儀 37 3-3-6 雷射掃瞄共軛焦顯微鏡 37 3-3-7 紫外光可見光光譜儀 37 3-3-8 光激發螢光光譜儀 37 3-4 實驗方法 37 3-4-1 藥物與模擬藥物之釋放 37 3-4-2 海藻酸鈣崩解檢驗方法 39 3-4-3 細胞專一性吞噬檢驗方法 39 3-4-4 共軛焦顯微鏡樣品製備 40 3-4-5 細胞存活檢測方法 40 第4章 結果與討論 42 4-1 材料鑑定 42 4-1-1 中孔洞氧化矽奈米顆粒(Mesoporous Silica Nanoparticle,MSN) 42 4-1-2 海藻酸鈣球(Alginate bead,Alg) 45 4-1-3 海藻酸鈣包覆中孔洞氧化矽奈米球(MSN@Alg) 52 4-1-4 以RGD胜肽鏈修飾海藻酸鈣包覆中孔洞氧化矽顆粒(MSN@Alg-RGD) 56 4-1-5 海藻酸鈣包覆中孔洞氧化矽顆粒(MSN@Alg)崩解 58 4-2 釋放測試 62 4-2-1 中孔洞氧化矽顆粒對R6G吸附 62 4-2-2 搭載R6G之中孔洞氧化矽顆粒(R6G/MSN)與海藻酸鈣包覆搭載R6G之中孔洞氧化矽顆粒(R6G/MSN@Alg)釋放差異 62 4-2-3 搭載Dox之中孔洞氧化矽顆粒(Dox/MSN)與海藻酸鈣包覆搭載Dox之中孔洞氧化矽顆粒(Dox/MSN@Alg)釋放差異 76 4-3 標靶治療 77 4-3-1 藥物載體之生物相容性檢定 77 4-3-2 RGD配體對於avb3受體專一性測試 78 4-3-3 複合材料對於癌細胞之治療效果 84 第5章 結論 88 第6章 未來展望 89 參考文獻 90 | |
dc.language.iso | zh-TW | |
dc.title | 合成包覆中孔洞氧化矽奈米顆粒之海藻酸微米顆粒
應用於穩定釋放以及標靶化學治療 | zh_TW |
dc.title | Synthesis of Mesoporous Silica Nanoparticle Encapsulated Alginate Microparticles for Sustained Release and Targeting Chemotherapy | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林?輝(Feng-Huei Lin),張雍(Chang Yung),游佳欣(Jia-Shing Yu),蔡偉博(Wei-Bor Tsai) | |
dc.subject.keyword | 海藻酸,中孔洞氧化矽奈米顆粒,穩定釋放,細胞標定, | zh_TW |
dc.subject.keyword | alginate,mesoporous silica nanoparticle,sustained release,cell specific targeting, | en |
dc.relation.page | 94 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-07-31 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 化學工程學研究所 | zh_TW |
顯示於系所單位: | 化學工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 5.5 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。